Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:19:04 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:TARS - TARSUS PHARMACEUTICALS INC - http://www.tarsis.ca
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TARS - Q0.532.00·55.280.134.63+2.146.6446.514,9113,33832.71  34.63  32.0240.40  12.5716:02:20May 0115 min RT 2¢

Recent Trades - Last 10 of 3338
Time ETExPriceChangeVolume
16:02:20Q34.632.14119
16:01:36Q34.632.142,164
16:01:28Q34.632.14118
16:01:24Q34.632.14115
16:00:10Q34.632.141,476
16:00:10Q34.632.141,278
16:00:03Q34.632.1412
16:00:03Q34.632.148
16:00:03Q34.632.141,610
16:00:00Q34.632.1415

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-01 17:00U:TARSNews ReleaseTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
2024-04-23 08:30U:TARSNews ReleaseTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
2024-03-05 16:30U:TARSNews ReleaseTarsus to Participate at Upcoming Investor Conferences
2024-03-05 08:30U:TARSNews ReleaseTarsus Introduces "Mite Party" Campaign for XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
2024-03-01 00:08U:TARSNews ReleaseTarsus Announces Pricing of $100.0 Million Public Offering
2024-02-29 16:38U:TARSNews ReleaseTarsus Announces Proposed $100.0 Million Public Offering
2024-02-27 06:00U:TARSNews ReleaseTarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
2024-02-22 08:00U:TARSNews ReleaseTarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept ¢ € œTick-Kill ¢ €  Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
2024-02-20 17:00U:TARSNews ReleaseTarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
2024-01-31 17:00U:TARSNews ReleaseTarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
2023-12-11 08:00U:TARSNews ReleaseTarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 ‚  for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
2023-11-09 16:05U:TARSNews ReleaseTarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
2023-11-01 18:35U:TARSNews ReleaseTarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
2023-09-06 08:00U:TARSNews ReleaseTarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY ¢ „ ¢, the First and Only FDA Approved Treatment for Demodex Blepharitis
2023-08-30 16:30U:TARSNews ReleaseTarsus to Present at Upcoming Investor Conferences
2023-08-24 09:00U:TARSNews ReleaseNow Available ¢ € “ XDEMVY ¢ „ ¢ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
2023-08-10 16:05U:TARSNews ReleaseTarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
2023-08-01 22:31U:TARSNews ReleaseTarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
2023-07-31 16:30U:TARSNews ReleaseTarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
2023-07-25 07:00U:TARSNews ReleaseFDA Approves XDEMVY ¢ „ ¢ ‚  (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis